Astellas will pay $165 million upfront and another $130 million in June 2018 unless it terminates the agreement ahead of that time., a U.S. Affiliate of Astellas. ‘VelocImmune is the centerpiece of Regeneron's suite of technology for the discovery and advancement of individual monoclonal antibodies fully,’ said George D. Yancopoulos, M.D., Ph.D., President of Regeneron Study Laboratories and Regeneron's Chief Scientific Officer.’ ‘We are excited about this extension of the license contract with Regeneron,’ said Shinichi Tsukamoto, Ph.D., Astellas' Senior Vice President, Drug Discovery Study.’.. Astellas extends nonexclusive license contract with Regeneron for VelocImmune technology Regeneron Pharmaceuticals, Inc.The event may be the fourth of 10 national events. The event may also feature activities where the children will participate and find out about good nutrition and workout while they have fun. At the completion of the BEE Healthy* program they will be more informed about the significance of a wholesome lifestyle. Related StoriesResearchers discover rise in state-level obesity-related healthcare costsObesity groups take goal at claims that deny insurance of weight problems treatment under affordable treatment actStressed Latino parents doubly more likely to have children with obesity Stepping Stones Museum for Kids, a nonprofit organization committed to broadening and enriching the entire lives of children, and Norwalk Hospital will partner with GE Capital to perform the station activities.